Sorafenat
Sorafenat (Sorafenib 200 mg) — Natco multikinase inhibitor for advanced hepatocellular carcinoma, advanced renal cell carcinoma, RAI-refractory thyroid cancer.
✓ Medisch beoordeeld door Morgan Ellis — Apotheekonderzoeker · 8 jaar ervaring · Laatst beoordeeld: mei 2026
Snelle antwoord
Sorafenat — Sorafenib 200 mg (Natco Pharma). Multikinase inhibitor (VEGFR, PDGFR, RAF) for advanced hepatocellular carcinoma, advanced renal cell carcinoma, radioactive-iodine-refractory thyroid cancer.
Wat u krijgt bij MedsBase:
- WHO-GMP gecertificeerde fabrikant
- Discrete verpakking in een gewone envelop
- Wereldwijde verzending
- Beoordeeld door 1.400+ klanten (lees beoordelingen)
📦 Reshipment Assurance: als uw bestelling niet is aangekomen binnen 20 werkdagen na verzending, sturen wij het opnieuw zonder extra kosten. Lees het beleid.
Waarom bestellen bij MedsBase
Sorafenat ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialistisch begeleide kankertherapie — dit medicijn wordt gestart, gecontroleerd en gestopt door een oncoloog of hematoloog. Dosering hangt af van het tumortype, stadium, lichaamsoppervlak, orgaanfunctie en gelijktijdige therapie. Zelfbehandeling is niet geschikt; de onderstaande informatie is educatief en ondersteunt geïnformeerde gesprekken met uw specialist.
Tyrosine kinase inhibitors are oral targeted therapies. They require specialist initiation, ongoing therapeutic drug monitoring (where available), and management of class-specific toxicities. Adherence is critical — missed doses risk treatment failure. Most TKIs are CYP3A4 substrates with major drug interactions.
Veelgestelde vragen
What is a TKI?
Tyrosine kinase inhibitors block specific signalling pathways driving cancer cell growth. Each TKI is selective for different targets (EGFR for gefitinib/erlotinib; multikinase for sorafenib/sunitinib; BCR-ABL for nilotinib/imatinib; BTK for ibrutinib; JAK for ruxolitinib; CDK4/6 for palbociclib).
Bijwerkingen?
Class signature: rash (often correlates with response in EGFR inhibitors), diarrhoea, fatigue, hand-foot skin reaction, hypertension (multikinase), hepatotoxicity, QT prolongation. Each TKI has a specific profile.
Geneesmiddelinteracties?
Most TKIs are CYP3A4 substrates. Strong inhibitors (azoles, macrolides, ritonavir, grapefruit) raise levels and toxicity; strong inducers (rifampicin, phenytoin, carbamazepine, St John’s wort) drop levels and risk treatment failure.
Take with food?
Some TKIs (lapatinib, erlotinib) on empty stomach (food increases bioavailability variably). Others (gefitinib, sorafenib) with or without food. Specific instruction depends on the molecule — confirm with prescribing oncologist.
What about response monitoring?
Imaging (CT/MRI/PET) every 2-3 months early; tumour markers if applicable. Treatment continues while benefit; switch on progression or unacceptable toxicity.
Resistentie?
TKI resistance develops over time (typically 9-18 months in solid tumours). Mechanisms: target mutations (T790M for EGFR, T315I for BCR-ABL), alternate pathway activation, target overexpression. Next-generation TKIs (osimertinib, ponatinib) overcome specific resistance mutations.
Wat als ik een dosis vergeet?
Take when you remember if same day if >6 hours from next dose. Otherwise skip — do not double up. Specific instructions vary by drug; confirm with your oncology team.
Zwangerschap?
All TKIs are teratogenic — effective contraception during and for at least 4-6 months after for both partners.
Cardiac monitoring?
Multikinase TKIs (sorafenib, sunitinib): BP monitoring, ECG (QT), echocardiogram in selected cases. BCR-ABL TKIs (nilotinib): mandatory ECG at baseline and follow-up — QT prolongation.
Cost-effectiveness?
Generic TKIs are widely manufactured under voluntary licences in India and other jurisdictions. Indian generic prices are dramatically lower than branded equivalents. Quality and bioequivalence are well-documented.
Andere kankermedicijnen
- Xeloda — capecitabine 500 mg — oraal 5-FU prodrug voor borst-/colorectale-/maagkanker
- Altraz — anastrozole 1 mg — aromataseremmer voor postmenopauzale borstkanker
- Xbira — abiraterone 250 mg — CYP17-remmer voor gemetastaseerde prostaatkanker
- Zoldria — zoledronzuur IV — voor botmetastasen en hypercalciëmie
- Actorise — darbepoëtine alfa — voor chemotherapie-geïnduceerde anemie
Meer opties in antikankermedicatie
Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.
| Sterkte | 200 mg |
|---|---|
| Hoeveelheid | 120 Tablet/s, 240 Tablet/s |
| Farmaceutische vorm | Tablet/s |
| Fabrikant | Natco Pharma |
| Behandeling | Liver cancer, Kidney cancer, Thyroid cancer |
| Generiek merk | Sorafenib |
Sorafenat
Vragen & antwoorden
Sorafenat
Gerelateerde producten
Beoordelingen
Er zijn nog geen beoordelingen